Articles related to Surgical Oncology

National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.

The death of a 26-year-old woman diagnosed with metastatic cholangiocarcinoma at age 23 highlights challenges surrounding cancer recognition in younger adults, patient engagement through social media, and communication when treatment options become limited.

Recent compensation surveys place average U.S. oncologist earnings between approximately $360,000 and $465,000 annually, with variation driven by subspecialty, geography, experience level, and persistent demographic pay disparities.

Tranexamic acid was associated with lower rates of major bleeding among patients undergoing urologic surgery in a prespecified POISE-3 trial analysis, while thrombotic event rates remained similar between treatment groups.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.